US5523096A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Removal of selected factors from whole blood or its components
Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1995-06-06
•
Granted: 1996-06-04
•
Expires: 2015-06-06
Abstract
Abstract This invention provides a composition, device and method for the removal of selected factors, such as cytokines or pharmaceuticals, from a substance such as whole blood or plasma. Advantageously, the invention provides for the treatment or prevention of septic shock syndrome or other conditions evidenced by the presence of cytokines in a patient by contacting the patient's whole blood with a composition comprising silica and a surface treatment material, such as heparin, but preferably human serum albumin (HSA). The treatment lowers the cytokine concentration of the blood. Pharmaceuticals can be removed from an individual's whole blood or plasma, such as for use in treating drug overdosage.
Inventors
- 👤 Thomas B. Okarma
- 👤 John Blankenship
- 👤 Abraham T. Lin
- 👤 Mohammad A. Elkalay
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 01:16
CPC Classifications
A; A61; A61M; A61M1/00; A61M1/36; A61M1/3679; A61K; A61K35/00; A61K35/12; A61K35/14; A61M1/34; A61M1/342; A61M1/3424; A61M1/3431; A61M1/3621; A61M1/3643; A61M1/3644; A61M1/3672; A61M1/3673
Claims Analysis
Total Claims: 22
Claim 1
Independent Claim
93 words
A method for removing selected factors in a mammalian subject's blood, comprising steps of: contacting the blood with a composition of matter comprising amorphous, particulate non-spherical, silica and a silica pretreating agent wherein the silica pretreating agent is heparin or albumin and the pretreating agent is substantially devoid of covalent attachment to the silica, wherein the silica has a specific surface area of at least 150 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, whereby at least a portion of the selected factors are removed from the blood.
Claim 2
Independent Claim
93 words
A method for removing selected factors in a mammalian subject's blood, comprising steps of: contacting the blood with a composition of matter comprising amorphous, particulate non-spherical, silica and a silica pretreating agent wherein the silica pretreating agent is heparin or albumin and the pretreating agent is substantially devoid of covalent attachment to the silica, wherein the silica has a specific surface area of at least 150 m 2 /g, and contains between 0.5 cc/g and 2.5 cc/g of porosity, whereby at least a portion of the selected factors are removed from the blood.
Claim 3
Dependent Claim
24 words
The method of claim 1, wherein the specific surface area of the silica is between 150 m 2 /g and 1000 m 2 /g.
Claim 4
Dependent Claim
24 words
The method of claim 2, wherein the specific surface area of the silica is between 200 m 2 /g and 600 m 2 /g.
Claim 5
Dependent Claim
18 words
The method of claim 1 wherein the porosity of the silica is between 0.8 cc/g and 1.5 cc/g.
Claim 6
Dependent Claim
12 words
The method of claim 1 wherein the silica is substantially chemically unmodified.
Claim 7
Dependent Claim
19 words
The method of claim 1 in which the silica particles have a mean diameter less than about 1 mm.
Claim 8
Dependent Claim
20 words
The method of claim 6 in which the silica particles have a mean diameter between about 50 and 250 microns.
Claim 9
Dependent Claim
21 words
The method of claim 1 in which the silica has a mean pore diameter of about 30 Å to 300 Å.
Claim 10
Dependent Claim
21 words
The method of claim 8 in which the silica has a mean pore diameter of about 60 Å to 200 Å.
Claim 11
Dependent Claim
23 words
The method of claim 1 comprising albumin in which the albumin comprises between 1% and 25% by weight of the silica pretreating agent.
Claim 12
Dependent Claim
19 words
The method of claim 10 in which the albumin comprises between 2.5% and 5% of the silica pretreating agent.
Claim 13
Dependent Claim
26 words
The method of claim 1 in which the selected factors comprise cytokines, complement molecules, serotonin, histamine, cholesterol molecules, a myoglobin component, angiogenesis factor or a pharmaceutical.
Claim 14
Dependent Claim
25 words
The method of claim 1 further comprising a step of subjecting the subject's blood to a means for anticoagulating blood, whereby the blood is anticoagulated.
Claim 15
Dependent Claim
13 words
The method of claim 13 wherein the anticoagulating step comprises use of citrate.
Claim 16
Dependent Claim
15 words
The method of claim 13 wherein the anticoagulating step comprises use of citrate and heparin.
Claim 17
Dependent Claim
37 words
A method for treating a condition characterized by the presence of selected factors in a mammalian subject's blood, according to the method of claim 1 further comprising a step of introducing the contacted blood to the subject.
Claim 18
Dependent Claim
12 words
The method of claim 16 wherein the condition is septic shock syndrome.
Claim 19
Dependent Claim
12 words
The method of claim 16 wherein the condition is capillary leak syndrome.
Claim 20
Dependent Claim
12 words
The method of claim 16 wherein the condition is acute renal failure.
Claim 21
Dependent Claim
11 words
The method of claim 16 wherein the condition is pharmaceutical overdose.
Claim 22
Dependent Claim
30 words
The method of claim 16 wherein the selected factors comprise serotonin, histamine, complement molecules, cytokines, interferon, tumor necrosis factor (TNF), cholesterol molecules, angiogenesis factor, a myoglobin component, or a pharmaceutical.
References Cited (Backward Citations)
US3607857A
Cited
US4059685A
Cited
US4006059A
Cited
US3998946A
Cited
US4102746A
Cited
GB1536425A
Cited
US4072566A
Cited
DE3109123A1
Cited
US4787974A
Cited
US4420395A
Cited
US4472303A
Cited
US4728432A
Cited
JPS6158664A
Cited
US4748121A
Cited
US4883765A
Cited
US4861707A
Cited
US5294401A
Cited
WO1988009202A1
Cited
US4865841A
Cited
US5041079A
Cited
US4963265A
Cited
US5022988A
Cited
WO1990000903A1
Cited
US5437861A
Cited
US5421815A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1999-06-04 | 1999-12-04 | 2000-06-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2003-06-04 | 2003-12-04 | 2004-06-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2007-06-04 | 2007-12-04 | 2008-06-04 | $7700.00 | Window Closed / Lapsed |